Search

Your search keyword '"Chen, Mao-Yuan"' showing total 290 results
Start Over Author "Chen, Mao-Yuan"
290 results on '"Chen, Mao-Yuan"'

11. Association of Single-Nucleotide Polymorphism 3 and c553G> T of APOA5 with Hypertriglyceridemia after Treatment with Highly Active Antiretroviral Therapy Containing Protease Inhibitors in HIV-Infected Individuals in Taiwan

Author

Chang, Sui-Yuan, Ko, Wei-Shin, Kao, Jau-Tsuen, Chang, Lan-Yang, Sun, Hsin-Yun, Chen, Mao-Yuan, Hsieh, Szu-Min, Sheng, Wang–Huei, Chang, Shu-Fang, Liu, Wen-Chun, Wu, Cheng–Hsin, Hsu, Hui–Jen, Kao, Chuan–Liang, Lee, Chun-Nan, Hung, Chien-Ching, and Chang, Shan–Chwen

Published
2009
Full Text
View/download PDF

18. Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in HIV-infected individuals in Taiwan

Author

Chang, Sui-Yuan, Ko, Wei-Shin, Kao, Jau-Tsuen, Chng, Lan-Yang, Sun, Hsin-Yun, Chen, Mao-Yuan, Hsieh, Szu-Min, Sheng, wang-Huei, Chang, Shu-Fang, Liu, Wen-Chun, Wu, Cheng-Hsin, Hsu, Hui-Jen, Kao, Chuan-Liang, Lee, Chun-Nan, Hung, Chien-Ching, and Chang, Shan-Chwen

Subjects
HIV infection -- Care and treatment, HIV infection -- Genetic aspects, HIV infection -- Research, Single nucleotide polymorphisms -- Research, Highly active antiretroviral therapy -- Dosage and administration, Highly active antiretroviral therapy -- Patient outcomes, Hyperlipidemia -- Genetic aspects, Hyperlipidemia -- Development and progression, Health, Health care industry
Published
2009

19. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy

Author

Sheng, Wang-Huei, Kao, Jia-Horng, Chen, Pei-Jer, Huang, Li-Ming, Chang, Sui-Yuan, Sun, Hsin-Yun, Hung, Chien-Ching, Chen, Mao-Yuan, and Chang, Shan-Chwen

Subjects
Hepatitis B -- Diagnosis, Biological markers -- Research, HIV patients -- Medical examination, HIV patients -- Care and treatment, Highly active antiretroviral therapy -- Complications and side effects, Comorbidity -- Risk factors, Health, Health care industry
Published
2007

20. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study

Author

Sheng, Wang-Huei, Hung, Chien-Ching, Kao, Jia-Horng, Chang, Sui-Yuan, Chen, Mao-Yuan, Hsieh, Szu-Min, Chen, Pei-Jer, and Chang, Shan-Chwen

Subjects
Hepatitis B -- Patient outcomes, Hepatitis B -- Research, HIV infection -- Patient outcomes, HIV infection -- Research, Delta-associated agent -- Influence, Comorbidity -- Research, Health, Health care industry
Published
2007

25. Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation

Author

Hsieh, Szu-Min, Hung, Chien-Ching, Pan, Sung-Ching, Wang, Jann-Tay, Tsai, Hsing-chun, Chen, Mao-Yuan, and Chang, Shan-Chwen

Subjects
Immunity -- Research, Tuberculosis -- Physiological aspects, HIV infection -- Drug therapy, Health
Abstract

Doctors should be cautious about discontinuing anti-tuberculosis drugs in HIV patients who are taking AIDS drugs even if their immune system seems to recover. In a study of 13 HIV patients, cellular immunity against tuberculosis did not increase even though they were taking AIDS drugs.

Published
2000

26. Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study

Author

Hung, Chien-Ching, Chen, Mao-Yuan, Hsieh, Szu-Min, Sheng, Wang-Hwei, and Chang, Shan-Chwen

Subjects
Taiwan -- Health aspects, AIDS (Disease) -- Patient outcomes, Health
Abstract

The use of highly active antiretroviral therapy (HAART) in Taiwan has cut the mortality rate from AIDS by more than 50%. HAART has been provided free of charge to many AIDS patients since 1997.

Published
2000

37. Placental transmission of human parvovirus 4 in newborns with hydrops, Taiwan

Author

Chen, Mao-Yuan, Yang, Shiu-Ju, and Hung, Chien-Ching

Subjects
Parvovirus infections -- Care and treatment -- Research, Disease transmission -- Research, Infants (Newborn) -- Health aspects, Health
Abstract

Transmission routes of human parvovirus 4 (PARV4), a recently discovered member of the Parvoviridae family (1), are not fully understood; studies have suggested that PARV4 is transmitted predominantly through the [...]

Published
2011
Full Text
View/download PDF

45. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

Author

Liu Wen-Chun, Lo Yi-Chun, Sun Hsin-Yun, Sheng Wang-Huei, Hsieh Szu-Min, Chen Mao-Yuan, Cheng Chien-Yu, and Hung Chien-Ching

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Risk of pneumocystosis after discontinuation of primary or secondary prophylaxis among HIV-infected patients before CD4 counts increase to ≧200 cells/μL (early discontinuation) after receiving highly active antiretroviral therapy (HAART) is rarely investigated. Methods Medical records of 660 HIV-infected patients with baseline CD4 counts Results The incidence rate of pneumocystosis after HAART was 2.81 per 100 person-years among 521 patients who did not initiate prophylaxis or had early discontinuation of prophylaxis, which was significantly higher than the incidence rate of 0.45 per 100 person-years among 139 patients who continued prophylaxis until CD4 counts increased to ≧200 cells/μL (adjusted risk ratio, 5.32; 95% confidence interval, 1.18, 23.94). Among the 215 patients who had early discontinuation of prophylaxis after achievement of undetectable plasma HIV RNA load, the incidence rate of pneumocystosis was reduced to 0.31 per 100 person-years, which was similar to that of the patients who continued prophylaxis until CD4 counts increased to ≧200 cells/μL (adjusted risk ratio, 0.63; 95% confidence interval, 0.03, 14.89). Conclusions Compared with the risk of pneumocystosis among patients who continued prophylaxis until CD4 counts increased to ≧200 cells/μL after HAART, the risk was significantly higher among patients who discontinued prophylaxis when CD4 counts remained

Published
2010
Full Text
View/download PDF

47. Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure

Author

Chen Mao-Yuan, Sheng Wang-Huei, Hung Chien-Ching, Chang Sui-Yuan, Hsieh Szu-Min, and Chang Shan-Chwen

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Tipranavir (TPV) is a recently approved nonpeptidic protease inhibitor (PI) of HIV-1 and has been indicated for those infected with PIs-resistant HIV-1. However, in clinical practice, whether the HIV-1 from the patients with virological failure to the regimens containing first-line PIs remains susceptible to TPV/r may be questionable. Methods To assess the resistance levels to TPV of HIV-1 from patients with treatment failure to first-line PIs, patients who experienced virological failure were tested for genotypic resistance of HIV-1 since August 2006 in National Taiwan University Hospital. Patients were enrolled for this analysis if their failed regimens contained > 12 weeks of atazanavir or lopinavir/ritonavir (defined as ATV group and LPV/r group, respectively), but were excluded if they experienced both or other PIs. The levels of genotypic resistance to TPV/r were determined by TPV mutation score. Results Till May 2008, 21 subjects in ATV group and 20 subjects in LPV/r group were enrolled. The TPV mutation scores in subjects in LPV/r group were significantly higher than these in ATV group (median, 3 vs 1, P = 0.007). 95.2% subjects in ATV group and only 45% subjects in LPV/r group had an estimated maximal virological response to TPV/r (P < 0.001). The resistance levels to TPV/r correlated with the duration of exposure to first-line PIs, whether in ATV or LPV/r group. Conclusion Cross-resistance from first-line PIs may impede the effectiveness of TPV/r-containing salvage therapy. TPV/r should be used cautiously for patients with virological failure to LPV/r especially long duration of exposure.

Published
2009
Full Text
View/download PDF

48. Association between amebic liver abscess and Human Immunodeficiency Virus infection in Taiwanese subjects

Author

Chen Mao-Yuan, Hsieh Szu-Min, Hsu Meng-Shuian, Hung Chien-Ching, and Chang Shan-Chwen

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Purpose Invasive amebiasis is an emerging parasitic disorder in Taiwan, especially in patients diagnosed with human immunodeficiency virus (HIV) infection. Thirty-three Taiwanese subjects with amebic liver abscess (ALA) were examined and a possible correlation between ALA and HIV infection was investigated. Results Among ALA patients, the proportion of HIV-positive individuals increased during the study period. ALA was the first major clinical presentation in 54% of HIV patients with ALA. Overall, 58% (14/24) of HIV-infected patients had a CD4+ count > 200 cells/μL and 82.1% (23/28) had no concurrent opportunistic infection or other evidence of HIV infection. There was no marked difference in clinical characteristics between HIV-positive and HIV-negative ALA patients except the level of leukocytosis. Conclusion While the clinical characteristics described herein cannot be used to determine whether ALA patients have HIV infection, routine HIV testing is recommended in patients with ALA, even in the absence of HIV symptoms.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results